Japan’s Nihon Trim Gets U.S. FDA Clearance For Warfarin Diagnostic
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has cleared Japan's Nihon Trim subsidiary TrimGen to market its genotyping kit for warfarin anti-coagulant. The TrimGen kits develop genetic profiles of patients to test how they would react to warfarin as a treatment against heart attacks, strokes or blood clots without suffering severe bleeding. Nihon Trim already has four other types of kits on the U.S. market, but the 90-minute TrimGen kit is the first designed for use with Roche's LightCyclere Real-Time PCR System. Nihon Trim plans to team with another pharmaceutical firm to sell the kits, as early as this summer. (Click here for more - a subscription may be required
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.